Pulsenmore Ltd. (NASDAQ:PLSM) experienced a sharp rally in its share price after the company announced it had been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, a joint initiative of the Israel Innovation Authority and the Ministry of Health. The company said it will receive funding as part of a project valued at $1 million.
The sandbox is structured to permit participating firms to develop and evaluate healthcare AI solutions in close collaboration with regulators and the health system. Pulsenmore said the program provides an avenue to develop and clinically validate AI applications intended to boost clinical workflow efficiency and to support wider deployment of its home ultrasound platform.
Pulsenmore's platform is designed to enable pregnant patients to perform physician-prescribed ultrasound scans at home using the company’s handheld ultrasound device paired with a smartphone. Each examination is transmitted to a physician for interpretation and subsequent clinical decision-making. The company noted that its technology is already in use by healthcare organizations, including Clalit Health Services, Israel’s largest Health Maintenance Organization.
According to the company, more than 250,000 home ultrasound scans have been performed using its platform, forming what Pulsenmore describes as the world’s largest real-world dataset of prenatal home ultrasound scans. The AI tools to be developed under the sandbox are intended to streamline clinicians’ workflow by automatically identifying key ultrasound parameters and surfacing findings for physicians to review.
As part of the project, Pulsenmore will work with Beilinson Hospital, a member of the Clalit Health Services network, on the development and clinical validation of the AI applications. The company highlighted clinical validation as a central element of the sandbox engagement.
Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, described the program as "the next stage in the evolution of our platform" and said the company aims to provide physicians with tools that let them "work more efficiently, focus on what matters most and care for more patients without compromising quality."
The regulatory sandbox is positioned as a mechanism to accelerate the adoption of healthcare AI technologies by creating a controlled environment in which companies can develop and test innovations alongside regulators and providers. For Pulsenmore, the program funds and collaborative framework are intended to support the technical and clinical steps required to validate AI features that automate interpretation work and present findings to clinicians.
Contextual note: The information above reflects the company announcement regarding selection for the Israel Healthcare AI Regulatory Sandbox Program and the related funding and collaborations described by Pulsenmore.